Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
A phase 2/3 trial of Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin in bladder & urothelial cancer, run by Vasgene Therapeutics, Inc, now recruiting.
Overview
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors is a phase 2/3 interventional study registered as NCT06493552 by Vasgene Therapeutics, Inc, with 700 participants planned, started 2025-03-15 and due to reach its primary completion in 2029-09. Interventions recorded: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin.
Similar pages
not linked directly; found by shared links- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Enfortumab vedotin, Gemcitabine, Cisplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Gemcitabine, Cisplatin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Shares Gemcitabine, Cisplatin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Shares Gemcitabine, Cisplatin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.